tbuckley/cabot-search huggingface dataset:
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Authors: H. Iwata, G. Rubovszky, S. Loibl, E. Ciruelos, M. Campone, D. Juric, H. Rugo, I. Mayer, P.F. Conte, B. Kaufman, K. Inoue, H. Tesch, Y.-S. Li, I.D. Mingorance, L. Ryvo, H. Iwase, A.-S. Longin, D. Mills, C. Wilke, F. Andre
Journal: Annals of Oncology (2016)
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
Authors: L. Paz-Ares, E.H. Tan, L. Zhang, V. Hirsh, K. O'Byrne, M. Boyer, J.C.-H. Yang, T.S.K. Mok, K.H. Lee, S. Lu, Y. Shi, S.-W. Kim, J. Laskin, D.-W. Kim, S. Laurie, K. Kölbeck, J. Fan, N. Dodd, A. Märten, K. Park
Journal: Annals of Oncology (2016)
Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort
Authors: Roni Shouval, Francesca Bonifazi, Joshua Fein, Cristina Boschini, Elena Oldani, Myriam Labopin, Roberto Raimondi, Nicoletta Sacchi, Osamah Dabash, Ron Unger, Mohamad Mohty, Alessandro Rambaldi, Arnon Nagler
Journal: American Journal of Hematology (2017)

Predictive models may help in determining the risk/benefit ratio of allogeneic hematopoietic stem cell transplantation (HSCT) in acute leukemia (AL). Using a machine-learning algorithm we have previously developed the AL- European Society for Blood and Marrow Transplantation (EBMT) score for prediction of mortality following transplantation. We report here the first external validation of the AL-EBMT score in a cohort of AL patients from the Italian national transplantation network. A total of 1848 patients transplanted between the years 2000-2014 were analyzed. The median age was 45.9. Indications for HSCT were Acute Myeloid Leukemia (68.1%) and Acute Lymphoblastic Leukemia (31.9%). The majority of patients were in first complete remission (60.4%), and received myeloablative conditioning (81.3%). Median follow-up was 2 years. The score was well-calibrated for prediction of day 100 mortality and 2-year overall survival (OS), leukemia free survival (LFS), and nonrelapse related mortality, with corresponding area under the receiver-operator curves of 0.698, 0.651, 0.653, and 0.651, respectively. Increasing score intervals were associated with a decreasing probability of 2-year OS and LFS. The highest scoring group was associated with a hazard ratio of 3.16, 2.8, and 2.27 for 2-year OS, LFS, and NRM, respectively. In conclusion, the AL-EBMT score identified three distinct risk groups and was predictive of OS. It is a valid tool for stratifying the risk of acute leukemia patients undergoing allogeneic HSCT.
A Randomized Controlled Trial of an Intensive Integrated Pest Management Intervention on Asthma Morbidity Among Children and Adolescents
Authors: Elizabeth Matsui, Matthew S. Perzanowski, Roger D. Peng, Robert A. Wise, Susan L. Balcer-Whaley, Michelle Newman, Amparito Cunningham, Adnan Divjan, Mary E. Bollinger, Shuyan Zhai, Ginger L. Chew, Rachel Miller, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2017)
Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua
Authors: L. Bellu, G. Lombardi, A. Pambuku, P. Fiduccia, A. Della Puppa, M.P. Gardiman, F. Berti, D. D'Avella, V. Zagonel
Journal: Annals of Oncology (2016)
Should We Prescribe Antibiotics to This Patient With Persistent Upper Respiratory Symptoms?
Authors: Howard Libman, Diane M. Brockmeyer, Howard S. Gold
Journal: Annals of Internal Medicine (2017)

The American College of Physicians (ACP) and the Centers for Disease Control and Prevention (CDC) recently published advice for high-value care on the appropriate use of antibiotics for acute respiratory tract infections. They conducted a narrative literature review of evidence for antibiotic use in this setting that included recent clinical guidelines from professional societies supplemented by randomized, controlled trials; meta-analyses; and systematic reviews. They concluded that clinicians should reserve antibiotic treatment for acute rhinosinusitis in patients with persistent symptoms for more than 10 days, high fever and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or worsening symptoms after a typical viral illness that lasted 5 days and had initially improved (“double-sickening”). In this Grand Rounds, 2 prominent clinicians debate whether to initiate antibiotic treatment in a 62-year-old man with a history of recurrent sinusitis who presents with persistent upper respiratory symptoms. They review the data on which the ACP/CDC recommendations are based and discuss the potential benefits and risks, as well as the challenges and controversies, of prescribing antibiotic therapy in this setting.
The feasibility and utility of a protein sparing modified fast (PSMF) in obese endometrial cancer survivors: A pilot study.
Authors: Thomas Patrick Lawler, Mary Beth Kavanagh, Christa Irene Nagel, Kristen Taylor Ruckstuhl, Sareena Singh, Kimberly Erin Resnick
Journal: Journal of Clinical Oncology (2016)

170 Background: Endometrial cancer affects 50,000 women a year. Obesity plays a significant role in the pathogenesis of endometrial cancer. Obese endometrial cancer survivors (ECS) are at significant lifetime risk of diabetes, cardiovascular disease (CVD), recurrence and death. There are no prospective studies examining the role of diet only in attempting to achieve weight loss in obese ECS. Protein sparing modified fast (PSMF), an approach to rapid weight loss, has been used to treat obesity in a safe manner. A pilot study is underway to investigate the feasibility of a PSMF for weight loss in this high risk population. Methods: To date, seven obese (BMI &gt; 30kg/m^2) ECS have been placed on a PSMF under the supervision of a physician and dietitian. Patients provided demographic information and Obesity Quality of Life (OQOL) questionnaire. Comprehensive metabolic panel with lipid panel and biomarkers of inflammation were drawn. Patients were instructed to eliminate carbohydrate containing foods and to augment with 1.2g/kg of protein per obesity-adjusted ideal body weight. Primary objectives are: total weight loss, subject retention, compliance, side effects, QOL and alterations in markers of obesity and inflammation. Results: The median age of the patient group was 56 years. Median baseline weight was 292.4 pounds (185.9-369). Median BMI was 44.5 kg/m2 (37.5-61.4). Mean baseline leptin level was 54.3 ng/ml (normal: 2.5-21.8). Mean baseline C-reactive protein level, a strong marker for CVD, was 4.574 (high risk for CVD &gt; 3). At 4 weeks median percent body weight lost was -6.48% (5.19%-7.00%). At 3 months the median loss nearly doubled to -13% (8.31%-14.11%). Significant reduction in CRP and leptin occurred in 2 patients: mean decrease was 3.9 and 28 points respectively. Conclusions: Our early data demonstrate that significant weight loss in obese endometrial cancer survivors is achievable in a standard outpatient gynecologic oncology practice. While long term follow up data and elucidation of the true significance of improvement in serum inflammatory markers are needed, we do know that even a 5-10% loss of body weight can lead to substantial improvement in CVD and diabetes risk.
Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines
Authors: Giada Bianchi, Vijay G. Ramakrishnan, Teresa Kimlinger, Jessica Haug, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2010)
International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM, GOELAMS, GELA, NCRI, ALLG
Authors: Veronique Leblond, Julie Lejeune, Olivier Tournilhac, Pierre Morel, marie Sarah Dilhuydy, Caroline Dartigeas, Marion Malphette, Bruno Royer, John F. Seymour, Sylvie Chevret, Steve Johnson, Roger G Owen
Journal: Blood (2011)
Erratum: Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations
Authors: Brian J O'Roak, Pelagia Deriziotis, Choli Lee, Laura Vives, Jerrod J Schwartz, Santhosh Girirajan, Emre Karakoc, Alexandra P MacKenzie, Sarah B Ng, Carl Baker, Mark J Rieder, Deborah A Nickerson, Raphael Bernier, Simon E Fisher, Jay Shendure, Evan E Eichler
Journal: Nature Genetics (2012)
Gene expression analysis of Notch signaling pathway receptors in colon cancer stem cells.
Authors: Ioannis Papasotiriou, Panagiotis Apostolou, Maria Toloudi, Marina Chatziioannou, Eleni Ioannou
Journal: Journal of Clinical Oncology (2012)

29 Background: The Notch signaling pathway is not only involved in cell differentiation, but also in carcinogenesis. Four different receptors are included in this pathway (Notch-1, Notch-2, Notch-3, and Notch-4) and each is encoded by a different gene. Recent data suggest that the activation of Notch-1 induces epithelial to mesenchymal transition (EMT) consistent with cancer stem cell (CSC) phenotype. It raises therefore the question of whether there is an interaction between the receptors. The present study aims to find out the gene expression patterns of Notch receptors in Colon CSCs, under the suppression of Notch-1. Methods: The experiments were performed in Colon CSCs provided by CELPOGEN. The stemness of these cells was tested both in gene and protein level with qPCR and flow cytometry assays for the stemness markers Oct4-CD44. The gene suppressed with RNAi assays and the knockdown was evaluated with molecular biology methods. The gene expression analysis was performed after RT-qPCR assays, by using the comparative Ct method (ΔΔCt) for the calculation of relative quantitation. Results: The Colon CSCs expressed Oct4-CD44 both in gene and protein level, indicating the stemness status. The knockdown of Notch-1 up to 75%, led to a reduction of gene expression in Notch-2 and Notch-3 receptors, while no significant difference was observed in Notch-4. The Notch-2 expression was decreased up to 90% while that of Notch-3 was at the same level with Notch-1. Conclusions: This research study attempts to find out any possible correlation between the Notch receptors in Colon CSCS. The experimental data indicate that Notch-1 interacts with Notch-2 and Notch-3 by affecting heavily their gene expression. It is therefore necessary to study if the other receptors are capable for EMT and then to find out which factors are involved. Further studies to a greater range of samples need to be performed, in order to use these data at clinical level.
Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017
Authors: Kazim Beebeejaun, Srilaxmi Degala, Koye Balogun, Ian Simms, Sarah Charlotte Woodhall, Ellen Heinsbroek, Paul David Crook, Ishani Kar-Purkayastha, Juli Treacy, Kate Wedgwood, Kate Jordan, Sema Mandal, Siew Lin Ngui, Michael Edelstein
Journal: Eurosurveillance (2017)

Between July 2016 and January 2017, 37 confirmed cases of hepatitis A with two unique IA genotype strains primarily among men who have sex with men, were reported across eight areas in England and Northern Ireland. Epidemiological and laboratory investigations indicate that these strains may have been imported several times from Spain, with secondary sexual transmission in the United Kingdom. Local and national public health services are collaborating to control this ongoing outbreak.
Implementing survivorship care planning in a large integrated cancer program.
Authors: Jamie Cairo, Carol Huibregtse, Adam Ferry, James L. Weese
Journal: Journal of Clinical Oncology (2016)

69 Background: Aurora Health Care is comprised of 15 hospitals and 22 oncology clinics. Aurora Cancer Care (ACC), a Commission on Cancer (CoC) accredited program, diagnoses and treats 7,000 adult cancer patients annually, more than any other healthcare system in Wisconsin. The CoC’s Survivorship Standard 3.3 requires accredited cancer programs to provide cancer patients with survivorship counseling and a written care plan. ACC was challenged to develop a consistent model of survivorship care that can work at multiple sites across the system. Methods: Workflow planning and education began at all oncology clinics in fourth quarter of 2014. Thirteen disease specific survivorship care plan templates were built into the EMR with some-auto population functionality. A system wide delivery plan was launched in first quarter of 2015 with the goal of targeting 10% of eligible patients. Initial focus was on breast cancer patients with some sites also including other cancers. The model of survivorship care is an “embedded consultation” in medical or surgical oncology with an advanced practice provider (APP) completing the care plan and meeting with the patient at the end of first line treatment. Results: Initial required volumes were estimated based on 2013 registry data with a goal of completing approximately 700 care plans in 2015 to meet the 10% CoC standard. During Q1 &amp; Q2 of 2015, 444 care plans were generated and given to patients, mostly for breast cancer survivors. The most significant barrier surrounded retrieving data from the EMR. Conclusions: Data from the first half of 2015 demonstrates success with the approach. Aurora Cancer Care will exceed the benchmark of 700 care plans. There has been a high level of engagement with the APPs who have taken ownership of survivorship care planning, contributing to the success of the program thus far. Because of difficulty retrieving data from the EMR, manual tracking was still required. Future modifications will address this and other barriers.
T Cells Bearing Anti-CD19- and/or Anti-CD38-Chimeric Antigen Receptors Effectively Abrogate Primary Double-Hit Lymphoma Cells
Authors: Keichiro Mihara, Tetsumi Yoshida, Yoshifumi Takei, Naomi Sasaki, Yoshihiro Takihara, Tatsuo Ichinohe
Journal: Blood (2016)
PREDIT model: PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion?
Authors: T. Grellety, S. Cousin, L. Letinier, P. Bosco-Levy, S. Hoppe, D. Joly, N. Penel, S. Mathoulin-Pelissier, A. Italiano
Journal: Annals of Oncology (2016)
Genetic variants in HLA are a significant risk factor for peanut allergy independent of asthma
Authors: Yuka Asai, Aida Al-Eslami, Loubna Akhabir, Moshe Ben-Shoshan, Andrew Sandford, Rick Chin, Stephen T. Cheuk, Jennie Hui, William (Bill) Musk, Michael Hunter, Alan James, Ann E. Clarke, Denise Daley
Journal: Journal of Allergy and Clinical Immunology (2017)
High Incidence of Fanconi Anemia in Patients with a Morphological Picture Consistent with Refractory Cytopenia of Childhood
Authors: Ayami Yoshimi, Charlotte M. Niemeyer, Irith Baumann, Stephan Schwarz-Furlan, Detlev Schindler, Wolfram Ebell, Brigitte Strahm
Journal: Blood (2011)
Serum ST2, but Not IL-33, Is Elevated in Children with Food Allergy Due to Low Dose Baked Milk
Authors: Yosuke Baba, Toshiyuki Yoneyama, Hiromichi Yamada, Susumu Yamazaki, Asuka Hong, Eisuke Inage, Mari Mori, Yoshikazu Ohtsuka, Masato Kantake, Toshiaki Shimizu
Journal: Journal of Allergy and Clinical Immunology (2017)
The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.
Authors: Gael Roue, Patricia Perez-Galan, Monica Lopez-Guerra, Neus Villamor, Elias Campo, Dolors Colomer
Journal: Blood (2007)
A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
Authors: Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S Raab, Thierry Facon, Ravi Vij, Darrell J. White, Donna Reece, Lotfi Benboubker, Jeffrey A. Zonder, Wei Deng, Glenn Kroog, Anil K Singhal, Sagar Lonial
Journal: Blood (2012)
Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis
Authors: Ye Fan, Jing Zhang, Cai-Yu Chen, Ying-Bin Xiao, Laureano D. Asico, Pedro A. Jose, Jian-Cheng Xu, Gui-Sheng Qian, Chun-Yu Zeng
Journal: Cardiovascular Research (2017)

Macrophage migration inhibitory factor (MIF) is an important proinflammatory mediator linked to arterial diseases. Although its inflammatory property such as macrophage recruitment is known for contributing to vascular pathogenesis, the direct effects of MIF on homeostasis and biological function of vascular smooth muscle cell (VSMC) that are crucial for development of arterial abnormalities, are poorly understood.We show that MIF is able to directly induce VSMC dedifferentiation, a pathophysiological process fundamental for progression of various arterial diseases. Mechanistically, MIF suppresses p68 protein, a crucial regulator of cell growth and organ differentiation, via activation of JNK and p38 MAPKs. siRNA targeting of p68 facilitated dedifferentiation state in VSMCs, whereas p68 overexpression blocked MIF-elicited transition. In addition, MIF decreased the expression of serum response factor (SRF) that governs VSMC differentiation marker genes transcription, through repression of p68 protein. Furthermore, we showed a previously uncharacterized molecular interaction between p68 and SRF by co-immunoprecipitation assay. p68 attenuated MIF-elicited suppression of SRF recruitment to VSMC-specific promoter. Finally, anti-MIF treatment could reverse VSMC dedifferentiation, preserve vascular function, and inhibit remodelling due to vascular injury.Our results demonstrate a novel mechanism for the regulation of VSMC differentiation by MIF involving p68 and SRF. Strategy for targeting of MIF could inhibit aberrant transition of VSMC in cardiovascular pathogenesis, and may be of therapeutic benefit in phenotype-related arterial remodelling.
Reciprocal Densities of CXCR4 and CD5 Define Subfractions of Chronic Lymphocytic Leukemia Clones Differing in Phenotype and Response to Environmental Stimuli: Towards a Better Definition of Targetable Components of Leukemic Clones
Authors: Rajendra N Damle, Sonal Temburni, Cristina Sison, Jaison Jain, Jacqueline C. Barrientos, Jonathan E. Kolitz, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2014)
Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation
Authors: Jens Hillengass, Sofia Ayyaz, Kerstin Kilk, Marc André Weber, Thomas Hielscher, Hans-Ulrich Kauczor, Stefan Delorme, Anthony D. Ho, Hartmut Goldschmidt, Kai Neben
Journal: Blood (2011)
EPID-06. PROTEIN-SPECIFIC ANTIBODY RESPONSES TO VARICELLA VIRUS IDENTIFIES LOWER REACTIVITY TO GLYCOPROTEIN E IN PREDIAGNOSTIC SERA FROM GLIOMA CASES COMPARED TO CONTROLS IN THE PLCO COHORT
Authors: Joseph Wiemels, Mi Zhou, Lucie McCoy, Helen Hansen, Stephen Francis, John Wiencke, Margaret Wrensch, Paige Bracci
Journal: Neuro-Oncology (2016)

A role for neurotropic viruses in glioma etiology is supported by epidemiologic and clinical observations. Glioma patients consistently report a lower history of clinical responses to Varicella (VZV, chickenpox and shingles), and prior evidence suggests that strong varicella responses are toxic to glioma cells. We hypothesized that patient-restricted response to Varicella virus may impact efficacy of immune response against glioma, affecting incidence of the disease as well as survival in those afflicted. We explored the serum antibody viral protein-restricted response against 99 VZV protein antigens using Nucleic Acid Programmable Protein Arrays (NAPPA) in prediagnostic serum samples from 131 glioma patients and 524 controls from the Prostate Lung Colorectal and Ovarian Cancer Cohort. Multivariable analyses were constructed to include all protein antigens, and covariates such as education, gender, and number of days from blood draw to diagnosis. Stepwise regression indicated a reduced risk for subjects with a response against Orf68 (glycoprotein E), the most abundant glycoprotein in varicella (OR = 0.39, 95% CI = 0.19-0.81, P = 0.02). When incorporating glioma clinical grade in statistical models, serum responses were significantly different by grade for proteins Orf20 (capsid protein), Orf26 (packaging protein), and Orf31 (envelope glycoprotein). These specific responses, particularly that of glycoprotein E, point towards immunologic targets for glioma prevention. Future research will map the most reactive peptides within the glycoprotein E protein.
Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Authors: Hun Ju Lee, Hagop M. Kantarjian, Deborah A. Thomas, Stefan Faderl, Charles Koller, Alessandra Ferrajoli, Elias Jabbour, Rebecca Garris, Partow Kebriaei, Richard Champlin, Gautam Borthakur, William G. Wierda, Jan A. Burger, Jorge E. Cortes, Susan O'Brien, Farhad Ravandi
Journal: Blood (2011)
221PD Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
Authors: L-T. Chen, C-P. Li, C-F. Chiu, Y-S. Shan, J.O. Park, J-S. Chen, J.S. Kim, K-M. Rau, F. de Jong, M. Pipas, B. Belanger, E. Wang, K-H. Lee, Y-J. Bang
Journal: Annals of Oncology (2016)
The SQ HDM Slit-Tablet Reduces Symptoms of House Dust Mite Allergic Rhinitis in Adolescents; A Subgroup Analysis of Results from a Dbpc Phase III Trial (TO-203-3-2)
Authors: Kaare Lund, Kazuhiro Okamiya, Keisuke Masuyama, Bente Riis
Journal: Journal of Allergy and Clinical Immunology (2017)
Detection of Chromosomal Aberrations in Acute Myeloid Leukemia By Copy Number Alteration Analysis of Exome Sequencing Data
Authors: Sebastian Vosberg, Luise Hartmann, Stephanie Schneider, Klaus H. Metzeler, Bianka Ksienzyk, Kathrin Bräundl, Martin Neumann, Claudia D Baldus, Alexander Graf, Stefan Krebs, Helmut Blum, Karsten Spiekermann, Stefan K. Bohlander, Ulrich Mansmann, Philipp A. Greif
Journal: Blood (2015)
Biomarkers of 12 SQ House Dust Mite Sublingual Immunotherapy (SLIT)-Tablet Treatment After Nasal Allergen Challenge
Authors: Natasha C. Gunawardana, Ashish Jain, Qing Zhao, Kuenhi Tsai, Laura George, Diana Selverian, Leon N. Carayannopoulos, Kaare Lund, Graham Clarke, Tim Mant, Trevor T. Hansel, Hendrik Nolte
Journal: Journal of Allergy and Clinical Immunology (2017)
Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML
Authors: Savitha Varatharajan, Ajay Abraham, Shaji R Velayudhan, Rayaz Ahmed, Aby Abraham, Biju George, Mammen Chandy, Alok Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian
Journal: Blood (2011)